Onconetix Stock (NASDAQ:ONCO)


RevenueOwnershipFinancialsChart

Previous Close

$4.50

52W Range

$2.80 - $21.40

50D Avg

$5.34

200D Avg

$6.31

Market Cap

$38.98M

Avg Vol (3M)

$853.06K

Beta

3.66

Div Yield

-

ONCO Company Profile


Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

12

IPO Date

Feb 18, 2022

Website

ONCO Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceJun 24Mar 24
Product$100.00K$100.00K

Fiscal year ends in Dec 23 | Currency in USD

ONCO Financial Summary


Dec 23Dec 22Dec 21
Revenue$58.47K--
Operating Income-$-13.48M$-3.42M
Net Income$-37.41M$-13.42M$-3.42M
EBITDA$43.94K$-13.54M$-3.41M
Basic EPS$-2.19$-1.09$-0.31
Diluted EPS$-2.19$-1.09$-0.31

Fiscal year ends in Dec 23 | Currency in USD